Resources Resource Type All Resources Poster (10) Presentation (5) Publication (27) Year All Years 2025 (4) 2024 (6) 2023 (6) 2022 (2) 2021 (5) 2020 (4) 2019 (1) 2018 (3) 2014 (3) 2011 (3) 2009 (1) 2007 (1) 2006 (1) 2005 (2) Search Found 42 Results May 30, 2025 Phase 1 Study Of Gotistobart (BNT316/ONC-392) In Combination With Lutetium 177 VipivotideTetraxetan (Lu 177) In Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Read more May 30, 2025 Gotistobart In Combination With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On PD-1 Inhibitors With Or Without CTLA-4 Inhibitors Read more January 13, 2025 pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4antibodies Read more September 15, 2024 PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer Read more July 19, 2024 PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF GOTISTOBART + PEMBROLIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (PROC) Read more July 19, 2024 PRESERVE-004/GOG-3081 (NCT05446298): A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer Read more 12345»
